Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081710 | 0.94 | FFAR4 (0.39) | FAAHPTGS2MTNR1AMTNR1BFFAR4 | |
| SCHEMBL2084249 | 0.93 | FFAR4 (0.44) | FAAHPTGS2MEN1KMT2AFFAR4 | |
| SCHEMBL2084837 | 0.92 | MTNR1A (0.43) | FAAHPTGS2MEN1KMT2AMTNR1A | |
| SCHEMBL2083153 | 0.89 | CNR1 (0.41) | FAAHPTGS2 | |
| SCHEMBL2087508 | 0.89 | CNR1 (0.39) | FAAHPTGS2 | |
| SCHEMBL2087122 | 0.89 | FAAH (0.38) | FAAHPTGS2 | |
| SCHEMBL2083383 | 0.88 | CNR1 (0.39) | FAAHPTGS2 | |
| SCHEMBL2085545 | 0.88 | CNR1 (0.40) | FAAHPTGS2 | |
| SCHEMBL2085477 | 0.88 | CNR1 (0.38) | FAAHPTGS2 | |
| SCHEMBL2085085 | 0.87 | CYP1A2 (0.41) | FAAHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863332-B2 | Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | FAAH 1231/4885PTGS2 625/4885MEN1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.